Starton Therapeutics utilizes proprietary dermal delivery technology to provide continuous administration of FDA-approved cancer therapies, enabling sustained drug exposure with the potential for improved efficacy. This approach addresses the limitations of traditional treatment regimens, allowing patients to experience better quality of life and extended survival.
Funding
$57M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies are administered via traditional methods that can result in fluctuating drug levels, leading to periods of overexposure and underexposure. This variability can reduce the therapy's effectiveness and increase the risk of adverse side effects, negatively impacting patients' quality of life and treatment outcomes.
Solution
Starton Therapeutics is developing a proprietary dermal delivery technology to provide continuous administration of FDA-approved cancer therapies. This approach aims to maintain sustained drug exposure within the therapeutic window, potentially improving efficacy and reducing toxicity compared to conventional bolus dosing. By delivering medication through the skin, Starton's technology seeks to transform standard-of-care cancer treatments, offering patients a more consistent and tolerable therapeutic experience. The continuous delivery method is designed to address the limitations of intermittent dosing schedules, leading to better patient compliance and enhanced clinical outcomes. This technology has the potential to improve the lives of people with cancer, allowing them to live better, longer.
Target Audience
The primary target audience includes individuals undergoing cancer treatment, oncologists, and healthcare providers seeking to improve the efficacy and tolerability of cancer therapies.
Features
- Proprietary dermal delivery system for continuous drug administration.
- Reformulation of FDA-approved cancer therapies for transdermal delivery.
- Designed to maintain consistent drug levels and minimize fluctuations.
- Potential for improved efficacy and reduced side effects compared to traditional methods.